ANGPT2 Antibody

What is the optimal method for detecting ANGPT2 antibodies in patient plasma samples?

ANGPT2 antibodies in plasma samples can be effectively detected using both immunoblot analysis and ELISA. For immunoblot analysis, a validated protocol involves running ANGPT2 in SDS gels, transferring to PVDF membranes, blocking with 5% BSA in PBS, and then incubating overnight with paired pretreatment and posttreatment plasma samples diluted 1×10³ fold. Detection is accomplished using HRP-conjugated goat anti-human IgG antibody and ECL visualization.

For ELISA detection, coat recombinant human ANGPT2 in TBS onto 96-well plates overnight, then rinse and block with a protein-free blocking solution for 1.5 hours at room temperature. Plasma samples should be diluted 500 to 2,000 fold in blocking solution containing 0.1% Tween-20 and incubated with coated ANGPT2 for 1 hour at 4°C. Include appropriate controls: wells coated with His tag as background controls and wells coated with ANGPT2 but without plasma to ensure signals originate from plasma antibodies .

What are the validated applications for commercial ANGPT2 antibodies?

Modern ANGPT2 antibodies have been rigorously validated for multiple applications:

Most commercial antibodies demonstrate reactivity with human, mouse, and rat ANGPT2, making them suitable for comparative studies across species .

How should ANGPT2 antibodies be purified from plasma for functional studies?

For functional studies requiring highly purified ANGPT2 antibodies from plasma, follow this research-validated protocol:

• Couple recombinant human ANGPT2 (6 μg) to activated NHS magnet beads (40 μL)

• Dilute plasma samples (600 μL) with an equal volume of PBS

• Incubate with ANGPT2-coupled beads with rotation at 4°C overnight

• Pull down beads using a magnet and wash with PBS 5 times

• Elute antibodies bound to ANGPT2 with 0.1 M glycine (pH 2.5)

• Neutralize immediately with 1/10 volume of 1 M Tris-Cl (pH 9.0)

• Concentrate using an Amicon Ultra filter

• Store in PBS supplemented with 0.02% BSA at 4°C

• Determine IgG content by ELISA against normal human IgG

This method yields functionally active antibodies suitable for characterizing their effects on ANGPT2-mediated signaling pathways and cellular responses .

What statistical approaches should be used when evaluating ANGPT2 as a biomarker in clinical studies?

When evaluating ANGPT2 as a biomarker in clinical trials, researchers should apply these specific statistical methodologies:

How should researchers design experiments to evaluate ANGPT2 as a prognostic biomarker for immune checkpoint therapy?

Based on published clinical research, design experiments as follows:

What are the best practices for reducing background when detecting ANGPT2 in Western blots?

When detecting ANGPT2 in Western blots, researchers frequently encounter background issues. Implement these empirically-validated approaches:

• Sample Preparation:

  • For supernatants of angiopoietin-expressing cells, use soluble Tie2 to precipitate angiopoietins and reduce background

  • Include appropriate controls: mock transfected cells alongside ANGPT2-expressing cells

• Blocking and Washing:

  • Block membranes with 5% non-fat milk in TBS

  • After primary antibody incubation, wash extensively with TBS-0.1% Tween (3 times, 5 minutes each)

• Antibody Dilution Optimization:

  • Use ANGPT2 antibody at 0.5 μg/mL concentration for overnight incubation at 4°C

  • Dilute secondary antibody (goat anti-rabbit IgG-HRP) at 1:5000 for 1.5 hours at room temperature

• Signal Development:

  • Use enhanced chemiluminescent detection (ECL) system

  • For challenging detections, consider longer exposure times while monitoring background development

Following this protocol, researchers should observe a specific band for ANGPT2 at approximately 66 kDa, although the expected band size is 57 kDa (the difference attributed to glycosylation) .

How can immunohistochemical detection of ANGPT2 in tumor tissue be optimized?

Optimizing immunohistochemical detection of ANGPT2 in tumor tissue requires specific technical considerations:

• Antigen Retrieval Protocols:

  • For ANGPT2, heat-mediated antigen retrieval in EDTA buffer (pH 8.0) provides optimal results

  • For double-staining with CD68, automated staining systems with ER1 solution (pH 6.0) for 30 minutes yield best results

• Detection Systems:

  • For ANGPT2 sections: Incubate with Novocastra Post Primary for 30 minutes, followed by Novolink Polymer for 30 minutes

  • Develop with diaminobenzidine, counterstain with hematoxylin

• Antibody Concentration and Incubation:

  • Use 1μg/ml rabbit anti-ANGPT2 antibody

  • Incubate overnight at 4°C after blocking with 10% goat serum

• Tissue-Specific Considerations:

  • ANGPT2 expression is observed in cytoplasm of tumor cells and endothelia of small blood vessels

  • For tumor tissue, biotinylated secondary antibodies and Strepavidin-Biotin-Complex (SABC) with DAB as chromogen have shown reliable results

These protocols have been successfully implemented across multiple tumor types including mammary cancer, placenta tissue, and rectal cancer samples .

How should researchers interpret conflicting ANGPT2 antibody-binding patterns observed in different tumor microenvironments?

Conflicting ANGPT2 antibody-binding patterns across tumor microenvironments require careful interpretation:

How can researchers differentiate between ANGPT2-specific antibody effects and non-specific binding in complex tissue samples?

Distinguishing specific from non-specific ANGPT2 antibody binding requires rigorous controls and validation:

• Essential Control Samples:

  • Include Matrigel-only implants (without cells) as critical background controls

  • Anti-ANGPT2 antibodies may show considerable staining of Matrigel alone

  • This background must be clearly delineated from specific UEA-1+ vessel staining

• Validation Through Multiple Detection Methods:

  • Complement protein detection with mRNA analysis (RNAscope)

  • Confirm antibody specificity using ANGPT2 knockdown samples

  • Verify that ANGPT2-shRNA decreases ANGPT2 expression at both mRNA and protein levels

• Specificity Confirmation Through Functional Studies:

  • Demonstrate that ANGPT2 knockdown alters biological phenotypes (e.g., shifts vessel size distribution)

  • Show that these effects mimic known ANGPT2 biology

• Technical Validation:

  • When using ANGPT2 antibodies, validate through multiple applications (WB, IF, IHC)

  • Confirm antibody specificity using tissues from ANGPT2 knockout models when available .

How can ANGPT2 antibodies be applied in studying the relationship between angiopoietin-2 and immune checkpoint therapy resistance?

ANGPT2 antibodies can be strategically employed to investigate immune checkpoint therapy resistance through these research approaches:

• Tumor Microenvironment Analysis:

  • Use ANGPT2 antibodies to characterize alterations in tumor vasculature before and after immune checkpoint therapy

  • Analyze ANGPT2 expression in correlation with CD68+ and CD163+ macrophage infiltration

  • Quantify changes in PD-L1 expression on macrophages in relation to ANGPT2 levels

• Mechanistic Studies:

  • Investigate how ANGPT2 promotes PD-L1 expression on M2-polarized macrophages

  • Analyze ANGPT2-mediated changes in tumor vascular ANGPT2 expression following treatment with immune checkpoint inhibitors

  • Study how ANGPT2 contributes to proangiogenic and immunosuppressive activities in the tumor microenvironment

• Therapeutic Combination Models:

  • Use neutralizing ANGPT2 antibodies in combination with immune checkpoint inhibitors to test potential synergistic effects

  • Analyze tumor growth, intratumoral microvessel density, and pericyte coverage as endpoints

  • Assess if ANGPT2 blockade can overcome resistance to immune checkpoint therapy

Research has shown that ANGPT2 may contribute to treatment resistance through increasing proangiogenic and immunosuppressive activities, making it a rational target for combinatorial approaches to improve immune therapy efficacy .

What methodologies should be used to study ANGPT2 mutations associated with primary lymphedema?

To study ANGPT2 mutations associated with primary lymphedema, researchers should implement this multifaceted approach:

• Genetic Analysis:

  • Perform automated DNA sequencing to detect ANGPT2 variants (particularly rs1868554 and rs7825407)

  • Analyze whole-gene deletions and heterozygous missense mutations

  • Use genomic DNA extracted from patients and healthy controls

• Expression Analysis:

  • Analyze ANGPT2 expression at mRNA level using real-time PCR

  • Determine angiopoietin-2 concentration in serum using validated ELISA methods

  • Correlate expression levels with clinical parameters and genetic variants

• Functional Assessment of Mutations:

  • Characterize missense mutations that affect ANGPT2 secretion or have dominant-negative effects

  • Evaluate effects of mutations (e.g., T299M, N304K) on TIE1 and TIE2 activation in human lymphatic endothelial cells

  • Use molecular modeling and biophysical studies to analyze how mutations affect ANGPT2 structure and function

• In Vivo Validation:

  • Express mutant ANGPT2 (e.g., T299M) in mouse skin to assess effects on lymphatic vessel morphology

  • Analyze for hyperplasia and dilation of cutaneous lymphatic vessels

  • Compare with wild-type ANGPT2 effects

Research has revealed that specific ANGPT2 mutations (such as T299M) can lead to reduced integrin α5 binding and promote hyperplasia and dilation of cutaneous lymphatic vessels, contributing to primary lymphedema .

How can researchers effectively utilize ANGPT2 antibodies to investigate novel Tie2 receptor clustering and activation mechanisms?

To investigate Tie2 receptor clustering and activation mechanisms using ANGPT2 antibodies:

• Structural Analysis Approaches:

  • Use ANGPT2 antibodies to study the binding interactions between ANGPT2 and the Tie2 receptor

  • Compare binding patterns of wild-type ANGPT2 versus mutant forms

  • Analyze how antibodies targeting different ANGPT2 domains affect receptor clustering

• Advanced Imaging Techniques:

  • Implement super-resolution microscopy with fluorescently-labeled ANGPT2 antibodies to visualize receptor clustering in real-time

  • Use FRET-based assays to measure molecular proximity and interactions

  • Apply single-molecule tracking to analyze dynamic receptor clustering events

• Functional Validation Studies:

  • Develop cellular assays using HEK293-Tie2 cell lines to measure Tie2 phosphorylation

  • Compare effects of ANGPT2-selective antibodies versus ANGPT2/ANGPT1 cross-reactive antibodies

  • Study how antibodies that target membrane-proximal fibronectin type III domains affect Tie2 clustering

• Therapeutic Development Applications:

  • Evaluate Tie2-agonistic antibodies that target domains distinct from the ANGPT-binding site

  • Assess how these antibodies induce polygonal Tie2 assemblies

  • Determine if antibody-induced Tie2 clustering is resistant to ANGPT2 antagonism

Recent structural studies have revealed that human Tie2-agonistic antibodies can tether preformed Tie2 homodimers into polygonal assemblies through specific binding to the Tie2 Fn3 domain, providing insights into novel activation mechanisms independent of ANGPT binding .

How can ANGPT2 antibodies be used to investigate the potential of angiopoietin-2 as a predictive biomarker for acetaminophen-induced acute liver failure?

Recent research has identified ANGPT2 as a promising prognostic biomarker for acetaminophen-induced acute liver failure. Researchers can investigate this using:

• Patient Cohort Analysis:

  • Measure circulating ANGPT2 levels from independent acetaminophen-ALF cohorts

  • Stratify patients based on time of symptom onset

  • Track ANGPT2 levels at multiple timepoints (day 1, day 3, etc.)

• Biomarker Evaluation Metrics:

  • Calculate AUROC values for ANGPT2 as predictor of non-survival

  • Compare ANGPT2 performance against established clinical scores (MELD)

  • Assess combination models (ANGPT2+MELD) for improved predictive accuracy

• Statistical Validation Framework:

  • Establish threshold values (approximately 11,000 pg/ml)

  • Determine sensitivity, specificity, and accuracy at optimal cutoffs

  • Validate in multiple independent cohorts

• Biological Mechanism Investigation:

  • Use single-cell RNA sequencing to confirm elevated ANGPT2 expression in endothelial cells following acetaminophen exposure

  • Correlate ANGPT2 expression with endothelial stress markers

  • Explore how ANGPT2 reflects vascular dysfunction in liver injury

Research data shows ANGPT2 outperforms MELD alone based on AUC values (ANGPT2: 0.87, MELD: 0.83, ANGPT2+MELD: 0.90), particularly in early-presenting patients, with day 1 and day 3 AUC values of 0.825 and 0.918, respectively .

What methodological approaches should be used to investigate ANGPT2 gene variants and their associations with multiple myeloma risk?

For investigating ANGPT2 gene variants and their associations with multiple myeloma (MM) risk:

• Genetic Analysis Methodology:

  • Extract genomic DNA from newly diagnosed MM patients and healthy blood donors

  • Analyze ANGPT2 variants (particularly rs1868554 and rs7825407) using automated DNA sequencing

  • Calculate odds ratios for specific genotypes (AA genotype of rs1868554, CC genotype of rs7825407)

• Expression Correlation Studies:

  • Determine ANGPT2 expression at mRNA level using real-time PCR

  • Measure angiopoietin-2 concentration in MM sera using ELISA

  • Correlate expression with clinical parameters (CRP, LDH)

• Statistical Analysis Framework:

  • Calculate odds ratios for MM risk associated with specific genotypes

  • Perform correlation analysis using Spearman's rho

  • Establish significance thresholds (p<0.05)

• Clinical Parameter Correlation:

  • Analyze relationships between ANGPT2 expression and established MM prognostic factors

  • Investigate how ANGPT2 protein levels compare between MM patients and healthy individuals

  • Consider ANGPT2 alongside other angiogenesis markers (VEGF, HB-EGF)

Research has shown individuals with the AA genotype of rs1868554 and the CC genotype of rs7825407 had significantly greater risk of developing MM (OR=6.12, p=0.02 and OR=6.01, p=0.02, respectively). ANGPT2 expression was positively correlated with CRP (Spearman's rho 0.26, p<0.05) and negatively correlated with LDH (Spearman's rho -0.25, p<0.05) in MM patients .